Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker EBS · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 7, 2026 | CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma NCT00893516 · T-cell Lymphoma CHOP + CD4, CHOP | EBS Emergent BioSolutions | Phase 2 | Terminated | 5 | Oct 2008 | Registry ↗ |
| Aug 19, 2026 | Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults NCT05377255 · Opioid Overdose 16 mg naloxone AP003, 8 mg naloxone NARCAN Nasal Spray | EBS Emergent BioSolutions | Phase 1 | Completed | 24 | May 10, 2022 | Registry ↗ |
| May 12, 2026 | VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infec… NCT01374984 · Complication of Smallpox Vaccination VIGIV | EBS Emergent BioSolutions | — | Enrolling by invitation | 100 | Aug 2027 | Registry ↗ |
| May 6, 2026 | VELOCITY: An Anthrax Vaccine Clinical Study NCT03877926 · Anthrax AV7909, BioThrax | EBS Emergent BioSolutions | Phase 3 | Completed | 3,689 | Aug 6, 2020 | Registry ↗ |
| Mar 17, 2026 | Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax NCT07478471 · Infections, Bacterial Collection of samples | EBS Emergent BioSolutions | — | Not yet recruiting | 10 | May 2030 | Registry ↗ |
| Feb 6, 2026 | A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax… NCT03569553 · Inhalational Anthrax AIGIV | EBS Emergent BioSolutions | — | Not yet recruiting | 100 | Jul 2027 | Registry ↗ |
| Feb 6, 2026 | Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With S… NCT03569514 · Anthrax AIGIV | EBS Emergent BioSolutions | — | Not yet recruiting | 10 | Jul 2027 | Registry ↗ |
| Feb 6, 2026 | Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a M… NCT02177721 · Infections, Bacterial Sample Collection | EBS Emergent BioSolutions | Phase 4 | Not yet recruiting | 100 | May 2035 | Registry ↗ |
| Jan 16, 2026 | BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients NCT02051062 · Botulism Blood sample collection | EBS Emergent BioSolutions | Phase 4 | Enrolling by invitation | 10 | Jul 31, 2028 | Registry ↗ |
| Dec 8, 2025 | Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Proph… NCT07268612 · Anthrax CYFENDUS | EBS Emergent BioSolutions | — | Not yet recruiting | 250 | Nov 2036 | Registry ↗ |
| Sep 8, 2025 | Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study NCT04067011 · Anthrax Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet | EBS Emergent BioSolutions | Phase 2 | Completed | 210 | Mar 5, 2020 | Registry ↗ |
| Jun 15, 2025 | Ciprofloxacin BioThrax Co-Administration Study NCT01753115 · Anthrax BioThrax, Ciprofloxacin | EBS Emergent BioSolutions | Phase 2 | Completed | 154 | Aug 2013 | Registry ↗ |
| Jun 8, 2025 | A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes t… NCT05142306 · SARS-CoV-2 Infection COVID-HIG | EBS Emergent BioSolutions | Phase 1 | Completed | 23 | Mar 28, 2022 | Registry ↗ |
| Jun 8, 2025 | A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adu… NCT04661839 · COVID-19 COVID-HIGIV, Placebo (saline) | EBS Emergent BioSolutions | Phase 1 | Completed | 28 | Jul 27, 2021 | Registry ↗ |
| Jun 3, 2025 | Study of SIAN Nasal Spray in Healthy Adults NCT05194358 · Cyanide Poisoning Stabilized Isoamyl Nitrite (SIAN) | EBS Emergent BioSolutions | Phase 1 | Completed | 47 | Sep 29, 2023 | Registry ↗ |
| Jan 20, 2025 | Universal Influenza A Vaccine in Healthy Adults NCT05155319 · Human Influenza UFluA 20 µg each antigen/dose, UFluA 60 µg each antigen/dose | EBS Emergent BioSolutions | Phase 1 | Completed | 27 | Oct 10, 2023 | Registry ↗ |
| Jan 15, 2025 | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults NCT05935917 · Smallpox Brincidofovir | EBS Emergent BioSolutions | Phase 1 | Completed | 44 | Aug 14, 2023 | Registry ↗ |
| Apr 9, 2024 | Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in… NCT01491607 · Anthrax BioThrax | EBS Emergent BioSolutions | Phase 3 | Completed | 200 | May 2012 | Registry ↗ |
| Apr 9, 2024 | Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy A… NCT00679172 · Typhoid Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (… | EBS Emergent BioSolutions | Phase 2 | Completed | 187 | Dec 2008 | Registry ↗ |
| Apr 4, 2024 | Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®) NCT00928577 · Smallpox | EBS Emergent BioSolutions | — | Completed | 14,108 | Dec 2014 | Registry ↗ |
| Mar 18, 2024 | Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (Z… NCT03624946 · Zika Virus Infection, Zika Virus Disease Zika Virus Immune Globulin (ZIKV-IG), Placebo | EBS Emergent BioSolutions | Phase 1 | Completed | 30 | Mar 6, 2019 | Registry ↗ |
| Mar 18, 2024 | Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Ad… NCT03315104 · Influenza A H3N2, Influenza A H1N1 FLU-IGIV, Placebo for FLU-IGIV | EBS Emergent BioSolutions | Phase 2 | Completed | 65 | Jun 17, 2019 | Registry ↗ |
| Mar 18, 2024 | A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 NCT03160339 · Adenoviral Infection PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine | EBS Emergent BioSolutions | Phase 1 | Terminated | 25 | Nov 27, 2017 | Registry ↗ |
| Mar 18, 2024 | Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected A… NCT02771730 · Healthy Volunteer, HIV Vaccine Ad4-mgag, Ad4-EnvC150 | EBS Emergent BioSolutions | Phase 1 | Terminated | 20 | Feb 2017 | Registry ↗ |
| Mar 18, 2024 | Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to He… NCT02696291 · Viral Infection UV-4B 30 mg oral solution, UV-4B 75 mg oral solution | EBS Emergent BioSolutions | Phase 1 | Terminated | 7 | Mar 2, 2017 | Registry ↗ |
| Mar 18, 2024 | VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV NCT02443623 · Smallpox Vaccine Adverse Reaction Vaccination with ACAM2000 | EBS Emergent BioSolutions | Phase 4 | Completed | 3,032 | Jul 2021 | Registry ↗ |
| Mar 18, 2024 | Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed NCT02339155 · Infections, Bacterial AVA, Raxibacumab | EBS Emergent BioSolutions | Phase 4 | Completed | 573 | Jan 3, 2017 | Registry ↗ |
| Mar 18, 2024 | Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Ora… NCT02061358 · Viral Infection UV-4B 3 mg, UV-4B 10 mg | EBS Emergent BioSolutions | Phase 1 | Completed | 64 | Jul 2015 | Registry ↗ |
| Mar 18, 2024 | A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector… NCT01979406 · Anthrax Infection AVA, Ad4-PA-1 | EBS Emergent BioSolutions | Phase 1 | Completed | 120 | Oct 2014 | Registry ↗ |
| Mar 18, 2024 | A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Lev… NCT01770743 · Anthrax AV7909, BioThrax | EBS Emergent BioSolutions | Phase 2 | Completed | 168 | Feb 2014 | Registry ↗ |
| Mar 18, 2024 | Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel NCT01540929 · Smallpox | EBS Emergent BioSolutions | — | Completed | 5,001 | Sep 2012 | Registry ↗ |
| Mar 18, 2024 | ACAM2000® Myopericarditis Registry NCT01395082 · Myocarditis, Pericarditis | EBS Emergent BioSolutions | — | Completed | 24 | Feb 4, 2019 | Registry ↗ |
| Mar 18, 2024 | Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) NCT01311674 · Healthy Volunteers hepatitis B vaccine, hepatitis B vaccine | EBS Emergent BioSolutions | Phase 3 | Terminated | 141 | Mar 11, 2011 | Registry ↗ |
| Mar 18, 2024 | Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults NCT01263691 · Bacillus Anthracis (Anthrax) Infection BioThrax, AV7909 Formulation 1 | EBS Emergent BioSolutions | Phase 1 | Completed | 105 | May 2012 | Registry ↗ |
| Mar 18, 2024 | VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV NCT01158157 · Smallpox Vaccine Adverse Reaction ACAM2000 | EBS Emergent BioSolutions | Phase 3 | Completed | 25 | Feb 14, 2012 | Registry ↗ |
| Mar 18, 2024 | Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenz… NCT01006798 · Bird Flu, Influenza Placebo, Ad4-H5-Vtn | EBS Emergent BioSolutions | Phase 1 | Completed | 166 | Sep 2011 | Registry ↗ |
| Mar 18, 2024 | Safety Surveillance Study of ACAM2000® Vaccinia Vaccine NCT00927719 · Smallpox ACAM2000® smallpox vaccine | EBS Emergent BioSolutions | — | Completed | 897,227 | Dec 31, 2017 | Registry ↗ |
| Mar 18, 2024 | HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma NCT00877656 · T Cell Lymphoma HuMax-CD4 | EBS Emergent BioSolutions | Phase 2/3 | Completed | 21 | Jan 2006 | Registry ↗ |
| Mar 18, 2024 | Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) NCT00845650 · Anthrax AIGIV 3.5 mg/kg, Gamunex 90 mg/kg | EBS Emergent BioSolutions | Phase 1/2 | Completed | 129 | Oct 2010 | Registry ↗ |
| Mar 18, 2024 | Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle NCT00636519 · Healthy Volunteers Botulism Antitoxin Bivalent (Equine) Types A and B, Botulis… | EBS Emergent BioSolutions | Phase 1 | Completed | 36 | Oct 2009 | Registry ↗ |
| Mar 18, 2024 | Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses NCT00360737 · Healthy Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE) | EBS Emergent BioSolutions | Phase 1 | Completed | 40 | Dec 2006 | Registry ↗ |
| Mar 18, 2024 | Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox… NCT00053495 · Smallpox Vaccinia virus: ACAM2000 smallpox vaccine, vaccinia virus (… | EBS Emergent BioSolutions | Phase 2 | Completed | 353 | Jun 2003 | Registry ↗ |
| Mar 18, 2024 | Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults NCT00053482 · Smallpox ACAM2000 Smallpox Vaccine, Vaccinia virus (calf lymph) smal… | EBS Emergent BioSolutions | Phase 2 | Completed | 357 | Apr 2003 | Registry ↗ |
| Mar 15, 2024 | BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulin… NCT02055183 · Botulism BAT | EBS Emergent BioSolutions | — | Completed | 162 | Jul 2017 | Registry ↗ |
| Mar 15, 2024 | BioThrax® (Anthrax) Vaccine in Pregnancy Registry NCT01653392 · Pregnancy Complications, Pregnancy Outcome Observational Intervention | EBS Emergent BioSolutions | — | Completed | 98 | Feb 2020 | Registry ↗ |
| Mar 15, 2024 | Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9) NCT01202695 · Anthrax AVP-21D9, Placebo | EBS Emergent BioSolutions | Phase 1 | Completed | 50 | Jun 2011 | Registry ↗ |
| Mar 15, 2024 | Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum NCT00448253 · Symptoms of Inhalational Anthrax NP-015 | EBS Emergent BioSolutions | Phase 1 | Completed | 92 | Aug 2008 | Registry ↗ |
47 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:30 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances